Clinical trialPhase 2Unknown
The Transformation of Locally Advanced Pancreatic Cancer.
Carrilizumab Combined With Apatinib Mesylate and Radiotherapy and Chemotherapy for the Transformation of Locally Advanced Pancreatic Cancer.
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 April 2021
- Expected end
- 1 April 2023
- Enrollment
- 30 participants
- Sites
- 2
- Primary outcomes
- Objective remission rate(ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 January 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy (paclitaxel (albumin binding) combined with gemcitabine and cisplatin) in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This trial is a prospective, observational, single-center, single-arm clinical research.Conversion treatment lasted for a total of 12 weeks, with one treatment cycle every two weeks.Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped